Skip to content

Transradial vs Transfemoral Group-Randomized Efficacy and Safety Trial for Cerebral Angiography:A Prospective, Multicenter, Cluster-Randomized Controlled, Open-Label, Blinded Endpoint Evaluation Study

Transradial vs Transfemoral Group-Randomized Efficacy and Safety Trial for Cerebral Angiography:A Prospective, Multicenter, Cluster-Randomized Controlled, Open-Label, Blinded Endpoint Evaluation Study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600125906
Enrollment
Unknown
Registered
2026-06-01
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular Disease

Interventions

Transradial Approach:Transradial approach for cerebral angiography
Transfemoral Approach:Transfemoral approach for cerebral angiography

Sponsors

Gansu Provincial Maternity and Child-care Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >18 years; 2.Patients requiring whole-brain cerebral angiography; 3.Objective evidence indicating suitability for both transfemoral and transradial cerebral angiography, with ultrasound-documented radial artery inner diameter =1.5 mm; 4.Signed informed consent; 5.Modified Rankin Scale (mRS) score =2;

Exclusion criteria

Exclusion criteria: 1.Positive right-sided Allen test or Barbeau test, or femoral artery occlusion (for the TFA group); 2.Local infection or trauma at the puncture site; 3.Coagulation abnormalities: INR >1.5 or platelet count <50 × 10?/L; 4.Presence of access vessel pathology or anatomical variation deemed potentially harmful to the subject, such as interrupted aortic arch, subclavian artery occlusion, or aortic dissection; 5.Pregnancy; 6.Planned or completed major surgery or severe trauma within the preceding 2 weeks; 7.Expected survival <5 years; 8.Severe cardiac, hepatic, renal, or other organ dysfunction; 9.Contraindication to contrast agent for cerebral angiography; 10.Inability to comply with follow-up;

Design outcomes

Primary

MeasureTime frame
Success rate of cerebral angiography;

Secondary

MeasureTime frame
Comfort level during cerebral angiography;Economic evaluation of cerebral angiography;Safety of cerebral angiography;

Countries

China

Contacts

Public ContactYin Rong

Gansu Provincial Maternity and Child-care Hospital

yin_rong_@163.com+86 931 6968002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026